Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, commented: "The development of these novel recombinant p-S65-Ub antibodies represents a significant advancement in mitochondrial research.

ImmunoPrecise played a crucial role in this project by applying its proprietary rabbit B Cell Select™ platform to isolate and generate highly specific antibodies that target phosphorylated ubiquitin ...

Streamline your presentation slideshow—and keep it consistent with the UB brand guidelines—by starting with one of our PowerPoint templates. Looking to include general information on some of the ...

"UB-312 immunization in participants with multiple system atrophy and Parkinson's disease has been safe, well-tolerated, and is able to produce antibodies detectable in serum and cerebrospinal ...

In June 2022, Vaxxinity (VAXX) said that Part B of the trial succeeded as UB-312 was well tolerated and led to aSyn antibody responses in patients with early PD.

We apologize, but this video has failed to load. The study focuses on the development of antibodies that detect damaged mitochondria, which are more common as we age. ImmunoPrecise played a crucial ...

In this latest randomized, double-blind trial on 20 patients diagnosed with Parkinson's disease, the antibodies were shown to ...

At UB, you have the unique opportunity to live with like-minded students in our popular Living Learning Communities. You’ll make friends more easily, have study partners right next door, and get ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) found its stock slumping Monday. The AI-driven biotherapeutic research and technology company announces its significant contribution to a groundbreaking ...

VICTORIA, British Columbia, October 28, 2024--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, ...